CLSD Earnings Prediction
The chart below shows how CLSD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CLSD sees a -2.92% change in stock price 10 days leading up to the earnings, and a +3.51% change 10 days following the report. On the earnings day itself, the stock moves by -4.89%. This data can give you a slight idea of what to expect for the next quarter's release.
CLSD Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.04M
20.84%
1053.33%
Gross Margin
--
--
--
Operating Margin
-571.68%
-30.38%
-93.22%
Net Margin
-740.66%
-31.34%
-91.22%
EPS
-0.10
-33.33%
-0.00%
No Data Available
CLSD Earnings Analysis
Clearside Biomedical, Inc. Common Stock Corporation (CLSD.O) Earnings Conference Call
Positive
Strong Liquidity Position: The company reported approximately $23.6 million in cash and cash equivalents as of September 30, 2024, indicating strong liquidity to support planned operations into the third quarter of 2025.
ODYSSEY Trial Success: The ODYSSEY trial results exceeded expectations, demonstrating the potential efficacy, safety, and versatility of CLS-AX for treating chronic diseases.
Regulatory Approval Success: The company has successfully navigated the drug device regulatory pathway to obtain commercial approval for XIPERE, the first FDA-approved product for suprachoroidal administration.
Microinjector Operational Success: The SCs Microinjector continues to provide safe and reliable delivery with well over 10,000 injections performed to date, showcasing operational success.
Geographic Atrophy Treatment Evaluation: The company is currently evaluating specific small molecules through in vivo models for potential treatment of geographic atrophy, a market valued at over $20 billion in sales.
Negative
Third Quarter Financial Results: O u r f i n a n c i a l r e s u l t s f o r t h e t h i r d q u a r t e r 2 0 2 4 w e r e p u b l i s h e d e a r l i e r i n o u r p r e s s r e l e a s e a n d a r e a v a i l a b l e o n o u r w e b s i t e .
Cash and Cash Equivalents: A s o f S e p t e m b e r 3 0 , 2 0 2 4 , o u r c a s h a n d c a s h e q u i v a l e n t s t o t a l e d a p p r o x i m a t e l y $ 2 3 . 6 m i l l i o n .
Sufficient Funding Resources: W e b e l i e v e w e h a v e s u f f i c i e n t r e s o u r c e s t o f u n d o u r p l a n n e d o p e r a t i o n s i n t o t h e t h i r d q u a r t e r o f 2 0 2 5 .
Pipeline Expansion Planning: T h i s s u p p o r t s p l a n n i n g f o r C L S - A X P h a s e 3 p r o g r a m a n d r e s e a r c h w o r k t o e x p a n d o u r p i p e l i n e i n t o g e o g r a p h i c a t r o p h y .
Upcoming Healthcare Conference Participation: W e l o o k f o r w a r d t o p a r t i c i p a t i n g i n t h e S t i f e l H e a l t h c a r e C o n f e r e n c e n e x t w e e k , a n d w e w i l l c o n t i n u e t o u p d a t e y o u o n o u r p r o g r e s s .
CLSD FAQs
How does CLSD typically perform around its earnings report dates?
Is Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CLSD Earning Call Sentiment
Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript
1.0x
00:00
00:00
CLSD.O
-0.34%Positive
The earnings call summary presents a mixed outlook. The company has a solid cash position and plans for Phase 3 trials, but faces significant regulatory, competitive, and financial risks. The Q&A section indicates positive reception to study data and differentiation in product offerings, but management's avoidance in discussing Phase 3 costs raises concerns. The lack of new partnerships or strong financial metrics and guidance further supports a neutral sentiment. Without market cap data, the impact on stock price remains uncertain, but the overall sentiment suggests minimal movement.